YIDU TECH (02158) Interim Performance for the 2026 Fiscal Year: Adjusted EBITDA Doubles, New Orders Surge, Accounting Statements Approaching Breakeven

On November 27, YIDU TECH (02158) announced its mid-term performance for the 2026 fiscal year and held a performance briefing. During the reporting period, the company's business maintained healthy growth, with total revenue reaching 358 million yuan, an increase of 8.7% year-on-year. Of particular note is the significant improvement in the company's profit quality and operational efficiency: the company's adjusted EBITDA for existing businesses doubled compared to the same period last year, to approximately 54 million yuan, and the financial statements achieved nearly breakeven, one year ahead of the company management's previous expectations. The growth momentum of the business is strong, with a significant increase in new orders in core sectors. Among these, the big data platform and solutions sector saw a 19.7% year-on-year increase in new orders, and the life science solutions sector saw a 61.1% year-on-year increase in new orders. During the meeting, the management stated: "Currently, the company's large-scale model technology has entered a new stage of 'multi-point blooming, scaling deployment'. This judgment is based on the deployment in three dimensions: first, deep application in top hospitals, with the company's AI mid-platform deployed in more than 30 Class III hospitals, and the Doctor Copilot experiencing nearly a thousand high-frequency calls per day in a single hospital; second, precise empowerment of key specialties, with a significant improvement in the accuracy of TNM staging evaluation intelligent body; third, intelligent integration of top experts, the company is using the doctor's 'digital alter ego' to more widely serve patients with the expertise of experts. " YiduCore continues to evolve, achieving precise breakthroughs in model performance As the company's core algorithm engine, YiduCore made breakthrough progress during the reporting period, continuously enhancing medical insight precision and algorithm intelligence levels through the strengthened closed-loop of "data-driven algorithms, algorithm-enabled scenarios, scenario-fed data". As of September 30, 2025, YiduCore has analyzed more than 1.3 billion patient visits and nearly 7 billion authorized medical records, covering over 10,000 hospitals. The disease knowledge graph covers virtually all known diseases, and the specialty library covers 98 disease categories. At the same time, YIDU TECH continues to improve the performance of medical large models, addressing industry pain points of model "illusions" by controlling the occurrence rate to within 1% through means such as model training optimization, enhanced knowledge fusion, improved supervision mechanisms, and strengthened engineering controls. The self-developed MED-RAG architecture can achieve precise retrieval and efficient inference of complex medical knowledge. In the field of tumor diagnosis and treatment, the accuracy of TNM staging evaluation intelligent body's T staging has improved from 58% to 90%, and the N staging has improved from 62% to 80%, reaching the diagnosis level of chief physicians and providing strong support for precision tumor diagnosis and treatment. The cutting-edge technological capabilities have also been recognized by the industry, winning the "Medical NLP code auto-generation evaluation" championship and "Best Paper Award" at the 11th China Health Information Processing Conference (CHIP 2025). Full-chain value empowerment realization: Three major business sectors deeply penetrate and strongly land With the full-chain health ecosystem of "medical-pharmaceutical-insurance-patient" as its core, the company's three major business sectors demonstrate a positive development trend of "deep penetration, wide coverage, and strong landing." The revenue for the big data platform and solutions (AI for Medical) sector was 153 million yuan, an increase of 14.6% year-on-year. As of September 30, 2025, the company has provided solutions to 127 top Chinese hospitals and 44 regulatory agencies and policy makers. By driving both "data elements x AI technology," the company continues to solidify its data intelligence foundation while accelerating the large-scale implementation of intelligent applications, achieving value penetration from institutions to disciplines to individuals. In a certain cancer prevention and control center in southern China, YIDU TECH's Doctor Copilot has achieved nearly 1,000 daily calls, covering approximately 70% of medical personnel, and assisting doctors in serving over the cumulative 31,000 patients. The revenue for the life science solutions (AI for Life Science) sector was 138 million yuan. The company is committed to providing AI intelligence services for the entire life cycle of life science customers, with 17 of the top 20 multinational pharmaceutical companies as customers. During the reporting period, the company successfully supported the accelerated approval and listing of several innovative drugs, including the world's first infant hemangioma topical gel formulation, and the first innovative drug for slow hepatitis B. In the fields of rare childhood diseases and cell therapy, the company's real-world research (RWE) also made significant breakthroughs. In addition, YIDU TECH won two major projects from the National Health Insurance Administration, recognizing its ability in "AI + health insurance." The health management platform and solutions (AI for Care) sector delivered impressive results, with revenue reaching 66.67 million yuan, a year-on-year increase of 30.3%. The company maintains a leading position in the core cities' "Hui Min Bao" business, serving as the main operating platform for "Shenzhen Hui Min Bao" for three consecutive years and "Beijing Pu Hui Health Bao" for five consecutive years. Among these, "Shenzhen Hui Min Bao" saw its insured population surpassing 6.15 million during the reporting period, reaching a record high, and has served over 18 million people in the past three years. AI technology has significantly improved service efficiency, with over 85% of claim cases in "Beijing Pu Hui Health Bao" completed through quick claims, increasing claims efficiency by 60-70%. AI intelligent customer service accuracy rate exceeds 97%, with an online independent reception rate of 93%. As of now, the company has been deeply involved in the "Hui Min Bao" projects in 5 provinces and 13 cities, serving over 40 million insured users. In chronic disease management, the company's diabetes digital therapy has gradually expanded from the initial pilot area of Lingshui to Sanya, Wanning, Qionghai, Wenchang, and other areas, managing nearly 100,000 patients' health records, achieving a 27.04% increase in fasting blood sugar compliance. As of the end of the reporting period, the number of active transaction users on the health management platform has exceeded 22 million. Currently, medical artificial intelligence is moving from building technical capabilities towards a new cycle of systemic empowerment. The performance of YIDU TECH in the first half of the 2026 fiscal year validates the company's strategic direction and core value in the "medical-pharmaceutical-insurance-patient" full-chain health ecosystem. Looking ahead, we will continue to deepen the integration of large model technology with real-world scenarios around YiduCore, actively participating in the construction of an inclusive, efficient, and collaborative medical artificial intelligence infrastructure. The management stated, "We believe that sufficient cash reserves, continuously improved operational efficiency, and clear market strategies will support us in seizing the vast market opportunities in the future, achieving high-quality, sustainable growth, and creating long-term value for shareholders, customers, and society."